CG
APLS

Cutler Group’s Apellis Pharmaceuticals APLS Stock Holding History

Cutler Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$27K Sell
5,500
-21,700
-80% -$1.38M 0.01% 907
2023
Q4 		$52K Sell
27,200
-47,200
-63% -$2.39M ﹤0.01% 1425
2023
Q3 		$436K Buy
74,400
+58,800
+377% +$2.58M 0.04% 461
2023
Q2 		$33K Sell
15,600
-1,000
-6% -$86.3K ﹤0.01% 1544
2023
Q1 		$42K Sell
16,600
-12,200
-42% -$704K ﹤0.01% 1450
2022
Q4 		$242K Buy
28,800
+8,100
+39% +$430K 0.02% 698
2022
Q3 		$139K Buy
20,700
+6,000
+41% +$355K 0.01% 1175
2022
Q2 		$324K Buy
14,700
+9,200
+167% +$419K 0.02% 721
2022
Q1 		$102K Buy
+5,500
New +$243K 0.01% 1683
2021
Q4 		– Sell
-178,300
Closed -$732K – 5327
2021
Q3 		$732K Buy
178,300
+173,400
+3,539% +$9.74M 0.03% 595
2021
Q2 		$8K Buy
+4,900
New +$253K ﹤0.01% 4051
2020
Q3 		– Sell
-5,000
Closed -$8K – 4623
2020
Q2 		$8K Sell
5,000
-7,400
-60% -$238K ﹤0.01% 2990
2020
Q1 		$61K Sell
12,400
-500
-4% -$17.8K ﹤0.01% 1607
2019
Q4 		$51K Buy
+12,900
New +$357K ﹤0.01% 1611

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cutler Group's APLS Position: Q1 2024 in Review

Cutler Group sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 10,201 shares — an estimated $650K sold.

Cutler Group first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $3.35M in Q3 2021. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Cutler Group reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 10,201 Apellis Pharmaceuticals shares in Q1 2024, an estimated $650K.
  • Cutler Group first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
  • Cutler Group's Apellis Pharmaceuticals position peaked at $3.35M in Q3 2021.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.